JP2016500648A5 - - Google Patents

Download PDF

Info

Publication number
JP2016500648A5
JP2016500648A5 JP2015532963A JP2015532963A JP2016500648A5 JP 2016500648 A5 JP2016500648 A5 JP 2016500648A5 JP 2015532963 A JP2015532963 A JP 2015532963A JP 2015532963 A JP2015532963 A JP 2015532963A JP 2016500648 A5 JP2016500648 A5 JP 2016500648A5
Authority
JP
Japan
Prior art keywords
seq
peptide
active ingredient
conjugate according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015532963A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500648A (ja
JP6352923B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2013/008438 external-priority patent/WO2014046478A1/ko
Publication of JP2016500648A publication Critical patent/JP2016500648A/ja
Publication of JP2016500648A5 publication Critical patent/JP2016500648A5/ja
Application granted granted Critical
Publication of JP6352923B2 publication Critical patent/JP6352923B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015532963A 2012-09-19 2013-09-17 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 Active JP6352923B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
KR20120104173 2012-09-19
KR10-2012-0104144 2012-09-19
KR20120104144 2012-09-19
KR10-2012-0104173 2012-09-19
KR10-2012-0109207 2012-09-28
KR20120109216 2012-09-28
KR10-2012-0109216 2012-09-28
KR20120109207 2012-09-28
KR10-2013-0017169 2013-02-18
KR20130017169 2013-02-18
PCT/KR2013/008438 WO2014046478A1 (ko) 2012-09-19 2013-09-17 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018109473A Division JP6697028B2 (ja) 2012-09-19 2018-06-07 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物

Publications (3)

Publication Number Publication Date
JP2016500648A JP2016500648A (ja) 2016-01-14
JP2016500648A5 true JP2016500648A5 (cg-RX-API-DMAC7.html) 2016-11-10
JP6352923B2 JP6352923B2 (ja) 2018-07-04

Family

ID=50341699

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015532963A Active JP6352923B2 (ja) 2012-09-19 2013-09-17 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP2018109473A Active JP6697028B2 (ja) 2012-09-19 2018-06-07 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP2020076850A Active JP7041187B2 (ja) 2012-09-19 2020-04-23 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP2022037094A Active JP7368522B2 (ja) 2012-09-19 2022-03-10 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP2023176669A Active JP7742390B2 (ja) 2012-09-19 2023-10-12 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018109473A Active JP6697028B2 (ja) 2012-09-19 2018-06-07 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP2020076850A Active JP7041187B2 (ja) 2012-09-19 2020-04-23 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP2022037094A Active JP7368522B2 (ja) 2012-09-19 2022-03-10 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
JP2023176669A Active JP7742390B2 (ja) 2012-09-19 2023-10-12 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物

Country Status (8)

Country Link
US (4) US9902945B2 (cg-RX-API-DMAC7.html)
EP (3) EP2899200B1 (cg-RX-API-DMAC7.html)
JP (5) JP6352923B2 (cg-RX-API-DMAC7.html)
KR (3) KR102578890B1 (cg-RX-API-DMAC7.html)
CN (3) CN110074997B (cg-RX-API-DMAC7.html)
ES (2) ES2802253T3 (cg-RX-API-DMAC7.html)
TW (3) TWI655204B (cg-RX-API-DMAC7.html)
WO (1) WO2014046478A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150014483A (ko) 2012-05-11 2015-02-06 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
EP2875826B1 (en) 2012-05-11 2017-08-23 KAEL-GemVax Co.,Ltd Composition for preventing or treating sepsis
EP2873678B8 (en) 2012-07-11 2024-07-17 Gemvax & Kael Co., Ltd. Conjugate comprising a cell-penetrating peptide and compositions comprising same
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
ES2802253T3 (es) 2012-09-19 2021-01-18 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
TWI616530B (zh) * 2012-09-19 2018-03-01 傑姆維克斯&凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(一)
ES2999332T3 (en) * 2012-09-19 2025-02-25 Gemvax & Kael Co Ltd Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate
US9631184B2 (en) 2012-09-19 2017-04-25 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
ES2716870T3 (es) 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
ES2808076T3 (es) 2013-06-21 2021-02-25 Gemvax & Kael Co Ltd Regulador de la secreción hormonal, composición que lo contiene y procedimiento para controlar la secreción hormonal mediante su uso
BR112016008331B1 (pt) 2013-10-23 2023-01-31 Sang Jae Kim Composição para tratar e prevenir hiperplasia prostática benigna (bhp) e uso da dita composição para tratar e prevenir bhp
WO2015076621A1 (ko) 2013-11-22 2015-05-28 주식회사 카엘젬백스 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
JP6420459B2 (ja) * 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー,リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
CN106659149B (zh) 2014-04-30 2020-05-19 珍白斯凯尔有限公司 用于器官、组织或细胞移植的组合物、试剂盒和移植方法
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
ES2879641T3 (es) 2015-05-26 2021-11-22 Gemvax & Kael Co Ltd Octapéptidos antiinflamatorias, antifibróticos y cicatrizantes de heridas y las composiciones que los contienen
KR101647804B1 (ko) * 2015-06-24 2016-08-11 한국과학기술연구원 신규 세포투과 펩타이드 및 이의 용도
WO2017003267A1 (ko) 2015-07-02 2017-01-05 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
CA2996951C (en) * 2015-08-28 2024-05-07 The Medical College Of Wisconsin, Inc. Peptide inhibitors of telomerase translocation and therapeutic uses thereof
US10898540B2 (en) 2016-04-07 2021-01-26 Gem Vax & KAEL Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
KR101710186B1 (ko) * 2016-09-01 2017-03-10 (주)에이씨티 6-아미노헥사노산 유도체 및 그 유도체를 함유하는 광반응성 화장료 조성물
KR101843830B1 (ko) * 2016-09-27 2018-04-02 (주)라온크리에이트 피부 상태 개선 장치 및 그의 사용 방법
CN107168012A (zh) * 2017-07-11 2017-09-15 深圳市华星光电技术有限公司 一种彩色光刻胶及其制备方法
JP7262105B2 (ja) 2019-03-29 2023-04-21 国立研究開発法人理化学研究所 細胞透過性配列を有するポリペプチド及びそれを含む組成物
CN118754947B (zh) * 2020-09-03 2025-03-18 深圳厚存纳米药业有限公司 一种多肽及其多肽复合物纳米粒、核酸疫苗和应用
EP4324841A4 (en) 2021-04-15 2025-05-07 Onecuregen Co., Ltd. Cell-penetrating peptide, anticancer peptide and pharmaceutical composition for preventing or treating cancer therewith
KR102713418B1 (ko) * 2021-07-27 2024-10-07 ㈜에빅스젠 세포막 투과 펩티드 및 이를 포함하는 세포내 전달체
WO2023128122A1 (ko) * 2021-12-29 2023-07-06 주식회사 펩스젠 혈액뇌장벽 투과능을 가지는 펩타이드 및 이의 용도
KR102415717B1 (ko) * 2021-12-29 2022-07-05 주식회사 펩스젠 혈액뇌장벽 투과능을 가지는 신규한 펩타이드 및 이의 용도
KR102541402B1 (ko) * 2022-02-18 2023-06-14 주식회사 레메디 아토피 피부염 예방 또는 치료 활성을 가지는 펩타이드
WO2024117321A1 (ko) * 2022-12-01 2024-06-06 ㈜에빅스젠 세포막 투과 펩티드 및 이를 포함하는 세포내 전달체
CN119552212B (zh) * 2025-01-26 2025-04-25 杭州康源食品科技有限公司 一种具有降尿酸活性的三肽lfp及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI990655A7 (fi) * 1996-10-01 1999-06-01 Geron Corp Ihmistelomeraasin katalyyttinen alayksikkö
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6475789B1 (en) * 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US7585622B1 (en) * 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
US7078491B1 (en) 2000-09-21 2006-07-18 Amgen Inc. Selective binding agents of telomerase
US7294708B2 (en) * 2002-05-31 2007-11-13 Beijing Institute Of Biotechnology Telomerase reverse transcriptase fragments and uses thereof
US8128908B2 (en) 2004-04-30 2012-03-06 University Of Florida Research Foundation, Inc. Nanoparticles and their use for multifunctional bioimaging
EP1994942A1 (en) * 2007-05-25 2008-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising telomerase, and uses thereof
WO2009025871A1 (en) 2007-08-23 2009-02-26 University Of Medicine And Dentistry Of Nj Telomerase reverse transcriptase variant
EP3327030B1 (en) * 2007-09-25 2021-07-21 Pastoral Greenhouse Gas Research LTD Vaccines and vaccine components for inhibition of microbial cells
JP5787752B2 (ja) * 2008-06-16 2015-09-30 メディオラヌム・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ 抗腫瘍免疫療法
US8252282B2 (en) * 2008-06-19 2012-08-28 University Of Medicine & Dentistry Of New Jersey Nuclear telomerase reverse transcriptase variant
IT1393509B1 (it) * 2008-07-08 2012-04-27 Advanced Accelerator Applications S A Peptidi e loro uso come carrier in cellule cancerose
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
KR101169030B1 (ko) 2009-01-21 2012-07-26 애니젠 주식회사 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템
EP3581649A1 (en) * 2010-02-16 2019-12-18 Ultimovacs ASA Polypeptides
KR20150014483A (ko) 2012-05-11 2015-02-06 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US20170327802A1 (en) 2012-07-20 2017-11-16 Gemvax & Kael Co., Ltd. Anti-Inflammatory Peptides and Composition Comprising the Same
US9631184B2 (en) 2012-09-19 2017-04-25 Gemvax & Kael Co., Ltd. Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
ES2999332T3 (en) 2012-09-19 2025-02-25 Gemvax & Kael Co Ltd Cell penetrating peptide, conjugate comprising the same, and composition comprising conjugate
ES2802253T3 (es) 2012-09-19 2021-01-18 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
CN105535931A (zh) 2013-06-07 2016-05-04 凯尔杰姆维克斯有限公司 在癌症免疫疗法中有用的生物标记
KR102224965B1 (ko) 2013-07-12 2021-03-09 주식회사 젬백스앤카엘 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
WO2017066349A1 (en) 2015-10-13 2017-04-20 Symic Ip, Llc Ve-cadherin binding bioconjugate
CN106749537A (zh) * 2017-02-04 2017-05-31 北京大学第医院 一种多肽及其作为siRNA递送载体的应用

Similar Documents

Publication Publication Date Title
JP2016500648A5 (cg-RX-API-DMAC7.html)
JP2016500513A5 (cg-RX-API-DMAC7.html)
JP2015530404A5 (cg-RX-API-DMAC7.html)
JP2015530358A5 (cg-RX-API-DMAC7.html)
Wyatt et al. Applications of pHLIP technology for cancer imaging and therapy
Ruan et al. Stapled RGD peptide enables glioma-targeted drug delivery by overcoming multiple barriers
Kang et al. A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma
Chakraborti et al. Self-assembly of ferritin: structure, biological function and potential applications in nanotechnology
Belletti et al. Protein cage nanostructure as drug delivery system: magnifying glass on apoferritin
HRP20201973T1 (hr) Ligandi modificirani kružnom permutacijom kao agonisti i antagonisti
ES2661500T3 (es) Variantes de HMGB1 y sus usos
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
JP2011037872A5 (cg-RX-API-DMAC7.html)
WO2012149376A3 (en) Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same
WO2013056132A3 (en) Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
TN2015000177A1 (en) Anti-ceacam5 antibodies and uses thereof
JP2012504393A5 (cg-RX-API-DMAC7.html)
HRP20220519T1 (hr) Kombinacijska terapija ishemije
JP2010514779A5 (cg-RX-API-DMAC7.html)
HRP20121016T1 (hr) Sredstva i postupci za upravljanje interferencijom proteina
JP2014526881A5 (cg-RX-API-DMAC7.html)
JP2015522264A5 (cg-RX-API-DMAC7.html)
Noguchi et al. Effects of lyophilization of arginine-rich cell-penetrating peptide-modified extracellular vesicles on intracellular delivery
RU2016140214A (ru) Адресное воздействие на устойчивый к трастузумабу her2+ рак молочной железы посредством her3-нацеленных наночастиц
JP2012529293A5 (cg-RX-API-DMAC7.html)